131I Tositumomab

被引：0
|
作者：
Christine R. Culy
Harriet M. Lamb
机构：
[1] Adis International Limited,
来源：
BioDrugs | 2000年 / 14卷
关键词：
Fludarabine; Objective Response Rate; Autologous Stem Cell Transplant; Unlabelled Antibody; Tositumomab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
▴ 131I tositumomab is a radiolabelled murine anti-CD20 monoclonal antibody that binds specifically to the CD20 antigen on normal and malignant B lymphocytes. It has antitumour activity as a result of emission of beta particles, and activation of antibody-dependent cellular and complement-mediated cytotoxicity.
引用
收藏
页码：195 / 202
页数：7
相关论文
共 50 条
  • [1] 131I tositumomab
    Culy, CR
    Lamb, HM
    BIODRUGS, 2000, 14 (03) : 195 - 202
  • [2] 131I tositumomab -: A viewpoint by Wolfgang!Kern
    Kern, W
    BIODRUGS, 2000, 14 (03) : 203 - 203
  • [3] 131I tositumomab -: A viewpoint by Michael L!Grossbard
    Grossbard, ML
    BIODRUGS, 2000, 14 (03) : 203 - 204
  • [4] Tositumomab and iodine [131I] tositumomab in the management of follicular lymphoma -: An onocologist's view
    Davies, AJ
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 48 (04): : 305 - 316
  • [5] Long-term follow-up of patients treated with tositumomab and 131I tositumomab (BEXXAR™)
    Davies, A. J.
    Radford, J. A.
    Rohatiner, A. Z.
    Linton, K. M.
    Matthews, J.
    Johnson, P. W.
    Lister, T. A.
    ANNALS OF ONCOLOGY, 2008, 19 : 181 - 181
  • [6] Tositumomab and 131I therapy in non-Hodgkin's lymphoma
    Wahl, RL
    JOURNAL OF NUCLEAR MEDICINE, 2005, 46 : 128S - 140S
  • [7] Tositumomab and Iodine I 131 Tositumomab (Bexaar)
    Srinivasan, A.
    Mukherji, S. K.
    AMERICAN JOURNAL OF NEURORADIOLOGY, 2011, 32 (04) : 637 - 638
  • [8] I-131 tositumomab
    William, Basem M.
    Bierman, Philip J.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2010, 10 (08) : 1271 - 1278
  • [9] A clinical and scientific overview of tositumomab and iodine I 131 tositumomab
    Zelenetz, AD
    SEMINARS IN ONCOLOGY, 2003, 30 (02) : 22 - 30
  • [10] Development of 131I-tositumomab
    Lewington, V
    SEMINARS IN ONCOLOGY, 2005, 32 (01) : S50 - S56
12345